中国制药企业研发国际化的影响因素综合研究

摘要

中国制药企业研发国际化(Drug Product Internationalization,简称DPI)可能受到多个企业层面因素的影响.然而,现有的研究主要针对单一或少数几种因素进行分析,而忽视了各项因素之间相关程度及对制药企业的综合影响.本研究旨在探究企业层面因素对选择DPI模式的中国制药企业的综合影响.采用t检验和卡方检验,探讨有无DPI模式公司之间的差异.继而运用Logistic回归分析探讨16种企业层面影响因素变量对制药企业产生的综合影响.通过实证分析,本研究发现企业创新能力和知识吸收能力是影响医药企业发展和影响中国企业DPI模式选择的企业层面因素.同时,高级管理团队的受教育程度也与制药公司的DPI模式选择有显著的正相关关系.本研究结果为制药企业选择DPI模式提供了理论和实证依据.研究表明,中国制药企业的研发国际化水平仍处于初级阶段.从长远来看,中国制药企业应加强研发国际化水平,从而促进企业发展,改变国际药品市场格局.%Drug product internationalization (DPI) can be affected by multiple firm-level factors.However,existing studies mainly focus on a single or several factors and the deviation generated by the factors' effects on each other has been neglected.We aimed to study the comprehensive influences of firm-level factors on Chinese pharmaceutical firms that chose the DPI mode.Student's t tests and Chi Square tests were used to explore the differences between firms with or without DPI modes.Then,logistic regression analysis was used to explore the comprehensive impacts of these 16 variables.Through empirical research,we found the factors influencing the DPI mode of Chinese pharmaceutical enterprises and the firm-level factors that influenced DPI mode selection.This study showed that the capacity of enterprise's innovation and knowledge absorption were related to the mode selection.Moreover,the education of the top management team significantly contributed to the DPI mode selection of pharmaceutical firms.This study also provided theoretical and empirical evidence for pharmaceutical enterprises when choosing their DPI mode.The internationalization of Chinese pharmaceutical firms remained at the early stage.However,the internationalization of drug products from China would affect the international pharmaceutical supply in the long term.